---
trial_id: 259
discovery_date: 2022-03-29 21:28:28.001979
date: 2022-03-29 21:28:28.001979
title: "Randomized autologous hematopoietic stem cell transplantation versus alemtuzumab, cladribine or ocrelizumab for patients with relapsing remitting Multiple Sclerosis"
summary: |
  <p>EudraCT Number: 2017-001362-25<br />Sponsor Protocol Number: RAM-MS<br />Sponsor Name: Helse Bergen HF, Haukeland University Hospital<br />Start Date: 2018-05-02<br />Medical condition: Relapsing remitting multiple sclerosis.<br />Disease: <br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-001362-25/SE">SE</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-001362-25/DK">DK</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-001362-25/NL">NL</a> (Ongoing)</p>
link: 'https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-001362-25'
published_date: NaT
trial_source: Clinical Trials Register Europe
relevant: 
options:
  unlisted: false
---
<p>EudraCT Number: 2017-001362-25<br />Sponsor Protocol Number: RAM-MS<br />Sponsor Name: Helse Bergen HF, Haukeland University Hospital<br />Start Date: 2018-05-02<br />Medical condition: Relapsing remitting multiple sclerosis.<br />Disease: <br />Version: 21.1<br />SOC Term: 10029205 - Nervous system disorders<br />Classification Code: 10063399<br />Term: Relapsing-remitting multiple sclerosis<br />Level: PT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-001362-25/SE">SE</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-001362-25/DK">DK</a> (Ongoing), <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-001362-25/NL">NL</a> (Ongoing)</p>